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Abstract 
 The occurrence of stroke in humans peaks in the morning. A recent study revealed that 
time of day mitigates the therapeutic impact of neuroprotective paradigms. These findings 
might not only explain the previous failure of translation of neuroprotective therapies but 
inspire new paradigms in stroke chronopathophysiology research. Taking chronotype into 
account may complement the many factors that influence efficacy of experimental therapies in 
stroke. 
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 Over the past two decades, numerous reasons have been discussed for the failure of 
classical neuroprotective paradigms in ischemic stroke to translate successfully to clinical 
practice. Many of those reasons relate to the predictive value of stroke models as well as 
preclinical study design limitations such as improper randomization and blinding strategies. 
Researchers learnt quickly from previous translational setbacks. Major improvements in 
methodological quality were achieved in the stroke field, which may now have outpaced other 
areas of cardiovascular research in this regard.1 Moreover, an increasing body of evidence 
suggests that animal models adequately reflect human stroke pathophysiology and outcome 
when used appropriately. Despite this, translational research on neuroprotectants remained 
futile. This refocused our attention from pretended fundamental limitations in preclinical 
research models and strategies to seemingly minor yet impactful design differences between 
preclinical and clinical studies.      
Recently, a potentially game-changing study revealed a surprising influence of 
treatment time on stroke outcome2, adding to translationally relevant study design differences.3 
A number of established neuroprotective paradigms (normobaric hyperoxia, radical 
scavenging, NMDA receptor antagonism) were evaluated for efficacy during the inactive (light 
phase) versus the active (dark phase) phase in nocturnal rodents after stroke. Major treatment 
effects were only seen for interventions during the inactive phase. A major reason for the 
phenomenon was a significantly smaller penumbra during the active phase. These findings are 
highly relevant and timely given the supposed renaissance of neuroprotective approaches in 
the reperfusion era.4 Indeed, treatments in clinical trials are predominantly performed during 
the day-time (human active phase) for logistical reasons. If temporally regulated physiology 
plays a role in the observed neuroprotective effects, this may partially explain the translational 
failure of neuroprotective treatments we were experiencing.  
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 Although novel and striking, these findings should not come as a major surprise. Many 
biological functions relevant for stroke pathophysiology are orchestrated by the circadian clock 
(Figure) and may thus be of relevance for therapeutic interventions. For instance, blood 
pressure shows a clear diurnal profile reaching its nadir at the end of the resting period. In turn, 
susceptibility to antihypertensive interventions varies throughout the day. Cerebral blood 
vessels undergo diurnal changes in vascular function that are relevant to pathology.5 Moreover, 
there is a circadian rhythm in leukocyte migration and function, including immune reactions.6 
Leukocytes egress the circulation and accumulate in tissues with a marked daily, temporal 
program. Leukocyte accumulation is mediated by increased adhesion molecule expression on 
endothelial cells during the active phase, and is proposed to contribute to worse outcome after 
myocardical infarct occurring in the wake phase versus the resting phase. This could also be of 
direct relevance to secondary neuroinflammatory damage and outcome after ischemic stroke. 
Finally, the circadian clock is believed to have an influence on redox homeostasis and thereby 
on neuronal antioxidative defense7 that is important for recanalization therapies and research 
on reperfusion injury. 
 
[Figure about here] 
 
What are the implications of these findings for future translational research? First, 
validation of time of day effects in diurnal model systems should be performed. Large animals 
may help with this as they are mostly diurnal and better reflect human brain anatomy and 
physiology. Large animal stroke models are increasingly used for assessing reperfusion 
therapies and are becoming more widely available8, paving the way for tandem reperfusion and 
neuroprotection studies.  
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Second, the relevance of circadian regulation for other experimental treatment 
strategies should be elucidated. For instance, pre- and postconditioning strategies are currently 
assessed as powerful supplementary therapies that may significantly improve stroke outcome.9 
Since such strategies predominantly utilize changes in local and systemic metabolic processes 
that are in turn modulated by circadian clocks, the effect of intervention time should be 
systemically investigated. Moreover, the impact of circadian rhythms should be considered 
when optimizing strategies measuring functional outcome that may reveal different results in 
the active versus the inactive phase.  
Deciphering time of day effects might be time consuming. A third, interim suggestion 
would be to alter current experimental practices when nocturnal species such rodents are used. 
Reversal of the light dark cycle in animal facilities will harmonise the sleep/wake behavior of 
animals and researchers. The data presented in Esposito et al.2 suggest that acute treatment of 
stroke patients with neuroprotective strategies over the day may not be effective. Thus, if only 
active (night) times were assayed in previous experiments, many neuroprotective strategies 
would have never been discovered. They likely have value but must be implemented 
appropriately with respect to chronobiological aspects. 
Fourth, circadian rhythms are important elements adding to the interplay of factors such 
as age, sex and comorbidities that can affect stroke outcome and therapeutic efficacy. The sheer 
number of these factors and therapeutically relevant combinations make it increasingly 
challenging to model them sufficiently in translational studies. A potential solution may be to 
more closely interlink preclinical and early-stage clinical studies. Selecting patient populations 
who reflect the preclinical cohorts in which best effects were seen may increase chances for 
successful therapeutic intervention.10 Selection of eligible patients might be extended beyond 
criteria such as stroke size or location and may include chronobiological aspects. Stroke 
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patients presenting at night may assigned to different trials than those presenting during the 
day. 
 In summary, the increasing knowledge on circadian clock regulation in stroke and 
therapeutic outcomes may open the door for new research directions in stroke research. 
Chrono(patho)physiology might help us to prevent missing out on neuroprotection just by 
sleeping away the right time for intervention.  
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Figure legend 
Processes relevant to ischemic stroke pathophysiology that are controlled by circadian clocks. 
